AVR
Anteris Technologies Global Corp.
NASDAQ · Healthcare · Medical - Devices · AU
$8.16
−3.09%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$8.29
From 52W high−22.80%
Volume1.81M
Market cap$795.26M
P/E (TTM)—
P/S (TTM)354.7x
Div yield—
Key dataSep 18, 2026
Open
$8.29
From 52W high
−22.80%
Volume
1.81M
Market cap
$795.26M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.4x
P/E (TTM)
—
RSI (14)
42.4
MomentumView details →
1D Return
−3.09%
YTD Return
+65.46%
SummaryUpdated Jun 1, 2026
Anteris Technologies Global Corp. (NASDAQ:AVR) is an Australian-based structural heart company that develops medical devices for treating aortic stenosis, a condition where the heart's aortic valve becomes narrowed and restricts blood flow. Founded in 1999 and headquartered in Toowong, Australia, the company went public on the NASDAQ in December 2024. Anteris focuses on creating innovative solutions for patients with heart valve disease, particularly through its transcatheter aortic valve replacement technology and proprietary anti-calcification tissue treatment.
Similar companies
Latest newsMore news →
Anteris Technologies Global Corp. granted equity awards to Vice Chairman and CEO Wayne Paterson, David St Denis, and Matthew McDonnell effective September 12, 2026.3d agoAnteris Technologies Global Corp. reported its Q2 2026 financial results, with H1 2026 revenues of $1.503 million, up 28% year-over-year, and a net loss after tax of $51.675 million for H1 2026.39d ago